RoosterBio is an innovative mesenchymal stem cell (MSC) company that is focusing on democratizing stem cell manufacturing and ushering in a new era of regenerative medicine. Â 2016 has been a massive year for the company, as it recently announced a collaboration with BioBridge Global, as well as a co-branding partnership with the global filtration, separation and purification leader, Pall Corporation. [Read more…]
Mesenchymal Stem Cells (MSCs)
Mesenchymal stem cells (MSCs) are a well-characterized population of adult stem cells that can differentiate into a variety of cell types (chondrocytes, osteoblasts, adipocytes, myocytes, and more).
Global Cooperation – MD Anderson and NIH to Fund Clinical Trial Combining Mesoblast Technologies
MD Anderson Cancer Center and National Institutes of Health to Fund Trial Combining 2 Proprietary Mesoblast Technologies for Rapid Engraftment of Stem Cell Transplants in Cancer Patients
New York, USA; and Melbourne, Australia; December 6, 2016: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that MD Anderson Cancer Center (MDACC) in Texas and the United States National Institutes of Health (NIH) will fund a clinical trial combining Mesoblast’s two synergistic proprietary technologies, Mesenchymal Precursor Cell (MPC)-based expansion and ex-vivo fucosylation of hematopoietic stem cells (HSCs) for cord blood transpl
antation in cancer patients. The trial will provide clinical data on whether the combination of these two technologies synergistically facilitates more rapid cord blood HSC engraftment for bone marrow transplant patients than can be achieved by either technology alone.
The number of allogeneic bone marrow transplants performed globally each year could be substantially increased beyond the current 30,000, for cancer and non-cancer indications, if safe and effective alternative sources of allogeneic HSCs are available, such as cord blood, for patients who cannot find a matched donor. Unfortunately, cord blood transplants are associated with prolonged engraftment times due to insufficient numbers and inadequate homing capacity of cord blood HSCs, adversely impacting their clinical outcomes. [Read more…]
U.S. FDA Accepts Biological Industries’ Drug Master File for NutriStem® hPSC Xeno-Free Medium
Recently, Biological Industries (BI) submitted a Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for purposes of moving its NutriStem® hPSC XF Medium toward being certified for clinical applications. The product is a defined, xeno-free (XF), serum-free (SF) medium that supports the growth and expansion of human induced pluripotent stem (iPS) and embryonic stem cells (ESCs). [Read more…]
CariCord Partners with Singapore’s CellResearch Corp to Join “Global Cord Registry” & Launch Cord Tissue Storage in U.S.
Singapore’s CellResearch Corporation has entered into an agreement with CariCord to provide umbilical cord tissue banking services within the United States. CariCord is the private cord blood and tissue banking partner of ClinImmune Labs at the University of Colorado.
As stated in the November 30, 2016, press release:
“CellResearch Corporation Pte Ltd (“CellResearch”), a Singapore-based company that specializes in stem cell technology, through its wholly owned subsidiary, CordLabs Pte Ltd (“CordLabs”), has entered into an agreement with CariCord Inc. (“CariCord”) to provide umbilical cord tissue banking services in the United States. CariCord is the private postnatal cord blood and tissue banking partner of ClinImmune Labs (“ClinImmune”) at the University of Colorado, Anschutz Medical Campus (“UCAMC”).
This agreement extends CellResearch’s on-going collaboration with ClinImmune. The two groups are already working together to obtain US Federal Drug Agency (“US FDA”) approval for Corlicyte™, a drug for the treatment of diabetic wounds. ClinImmune will produce the world’s first Current Good Manufacturing Practices (“cGMP”) cord lining mesenchymal stem cell lines for therapeutic use.”
This license agreement also allows CariCord’s cord tissue clients to join CellResearch’s Global Cord Registry (“GCR”), “a proprietary registry for all clients who have saved cord lining stem cells with licensed partners.” The registry currently has 50,000+ registered clients, making it the largest group of its type in the world.
To learn more, read the full press release from CellResearch Corporation.
Cord Blood Market Trends, by Region and Sub-Segment
The cord blood market is a complex international industry, composed of public, private, and hybrid cord blood banks.
These market participants store a range of varied products, including cord blood, cord tissue, and sometimes, related perinatal tissues and stem cell types. Rates of cord blood utilization for clinical use vary substantially as well.
Therefore, our approach to analyzing cord blood market trends is to look at it geographically, as well as by sub-segment according to blood units banked, tissue units banked, and clinical units transplanted.
A high level assessment of cord blood market growth is that North American is flat, North Asia and Southeast Asia (SEA) are growing by double digits, and Europe is declining.
We summarize these cord blood industry trends as follows:
To learn more, read our recent interview with Kenneth Harris of CuraSense Advisors, in which we discuss growth rates and trends within the global cord blood banking industry.
- « Previous Page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- …
- 58
- Next Page »